Sanofi Drug for Rare Blood Disease Is Heading to Recordati for $825M
Sanofi’s Enjaymo, the only approved drug therapy for a rare and debilitating blood disorder, is being acquired by Recordati in ...
Sanofi’s Enjaymo, the only approved drug therapy for a rare and debilitating blood disorder, is being acquired by Recordati in ...
Copyright © 2024 EuroAsia24 News.
EuroAsia24 News is not responsible for the content of external sites.